Amzell B.V. and Amring Pharmaceuticals Inc. Attending 2021 American Epilepsy Society Meeting in Chicago
BERWYN, Pa.--(BUSINESS WIRE)--Amzell B.V. (Amzell), a specialist development pharmaceutical company, and Amring Pharmaceuticals Inc. (Amring), a niche generics and value-driven brand company, announced today that they will be in attendance at the 2021 American Epilepsy Society (AES) Annual Meeting. The meeting will be held from Dec 3 to Dec 7, 2021, at McCormick Place West in Chicago, IL.
Amzell and Amring will be in attendance to discuss the upcoming U.S. Phase III Clinical Trial for the treatment of Infantile Epileptic Disease. Due to both in-person and virtual format of this meeting, please contact email@example.com to schedule a meeting or to learn more about the trial.
The Phase III Clinical Trial of AMZ002 was recently announced for use in the treatment of Infantile Spasms (IS) and will be one of the first trials to investigate co-primary endpoints assessing both the absence of spasms and the resolution of hypsarrhythmia.
For additional information about the annual AES meeting, please visit their website: https://www.aesnet.org/2021-annual-meeting
About Amzell B.V.
Amzell B.V. is a specialist development pharmaceutical company which takes candidate drugs and devices either through to proof of efficacy or through to marketing authorization for further commercialization in partnership with leading niche-based commercial healthcare companies. The company, based in Hoofddorp, The Netherlands, was founded in 2016. Amzell has particular interest in developing well-characterized, active pharmaceutical ingredients using innovation platform drug delivery technologies to provide more effective drug delivery, increased efficacy, and improved safety and compliance.
About Amring Pharmaceuticals
Amring Pharmaceuticals is a privately held pharmaceutical company that provides niche generics and value-driven brands to the market. Amring is partnered with well-established global biopharmaceutical companies and is uniquely positioned to leverage its expertise in bringing biotechnology derived medicines, sterile manufacturing, and other state of the art technologies to the marketplace.
This press release contains forward-looking statements, including, without limitation, statements related to Amring’s business developments and the implementation of Amring’s strategic initiatives. Because these statements reflect Amring’s current views, expectations, and beliefs concerning future events, these forward-looking statements involve risks and uncertainties that could cause actual developments and results to differ materially from Amring’s expectations. These factors include, but are not limited to, general market conditions, regulatory trends, changes in the financial conditions of third parties dealing with Amring, and other factors that could affect Amring’s business and financial performance. Amring does not assume any obligation to publicly updates any forward-looking statements, whether as a result of new information, future developments or otherwise.
Amring Pharmaceuticals Inc.
Marina Volin, Esq.
VP, General Counsel
Dario Carrara, PhD